Feasibility IDE study will be the first to evaluate responsive neuromodulation for a severe and disabling childhood-onset epilepsy MOUNTAIN VIEW, Calif. — June 30, 2021…
NeuroPace Inc.June 30, 2021
Funds will also support clinical trial to pursue new indication for the company’s life-changing neuromodulation technology MOUNTAIN VIEW, Calif. – August 31, 2020 – NeuroPace,…
NeuroPace Inc.August 31, 2020
Personalized, data-driven treatment for refractory focal epilepsy demonstrates unprecedented real-world results and exceptional long-term clinical data MOUNTAIN VIEW, Calif. – July 27, 2020 – NeuroPace,…
NeuroPace Inc.July 29, 2020
Full-body MRI opens up valuable medical imaging possibilities for RNS System patients MOUNTAIN VIEW, Calif. – March. 9, 2020 – NeuroPace, Inc., a Silicon Valley-based…
NeuroPace Inc.March 6, 2020
Real-world experience with the RNS System reveals best outcomes to date of any neuromodulation device for focal seizures MOUNTAIN VIEW, Calif. — December 9, 2019…
NeuroPace Inc.December 9, 2019
Industry veteran to drive business development, strategy and enhance customer experience MOUNTAIN VIEW, Calif. — July 30, 2019 – NeuroPace, Inc., a Silicon Valley-based medical…
NeuroPace Inc.July 31, 2019
Frank Fischer appointed Chairman of Board of Directors MOUNTAIN VIEW, Calif. - July 24, 2019 (BUSINESS WIRE)--NeuroPace, Inc., a Silicon Valley-based medical technology company, today…
NeuroPace Inc.July 24, 2019
Study Aims to Assess Whether Closed-Loop Neuromodulation Could Help Manage
Medically Refractory Obesity MOUNTAIN VIEW, Calif. — July 10, 2019 – NeuroPace, Inc., a Silicon…
NeuroPace Inc.July 10, 2019
Results Demonstrate Significant Seizure Reduction in Adults with Drug-Resistant Epilepsy; Insights into the Human Brain MOUNTAIN VIEW, Calif. — May 9, 2019 – NeuroPace, Inc.,…
NeuroPace Inc.May 9, 2019
